Genenta Science S.p.A.

NasdaqCM:GNTA Stock Report

Market Cap: US$51.9m

Genenta Science Balance Sheet Health

Financial Health criteria checks 5/6

Genenta Science has a total shareholder equity of €21.8M and total debt of €7.6M, which brings its debt-to-equity ratio to 34.8%. Its total assets and total liabilities are €31.9M and €10.0M respectively.

Key information

34.81%

Debt to equity ratio

€7.60m

Debt

Interest coverage ration/a
Cash€28.15m
Equity€21.84m
Total liabilities€10.05m
Total assets€31.89m

Recent financial health updates

Recent updates

Analysis Article Jan 26

We're Keeping An Eye On Genenta Science's (NASDAQ:GNTA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Jul 21

We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Dec 10

We're Not Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article Sep 09

We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha Jul 25

Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach

H.C. Wainwright has initiated stem cell gene therapy developer Genenta Science (NASDAQ:GNTA) as a buy seeing promise for the company's technology providing advantages differentiating elements over other cellular therapies for cancer. The firm has a $25 price target (269% upside based on Friday's close). Genenta shares are down 9% in early Monday afternoon tradig. Analyst Emanuela Branchetti said that the company's technology is "based on the ex-vivo lentiviral vector (LVV) mediated modification of autologous hematopoietic stem/progenitor cells (HSPCs) that deliver immunomodulatory molecules directly to the tumor." She highlighted four advantages/differentiating factors of Genenta's (GNTA) tech: 1. It focuses on a type tumor-associated myeloid cells (TEMs) that known to be involved in promoting angiogenesis and tumor growth; 2. It is built in a way that controls transgene expression and avoids off-target and systemic toxicity; 3. It has potential for long-tern durabiklity given the use of HSPCs; and 4) It is agnostic so it could potentially be used in a wide variety of cancers. Genenta's (GNTA) lead candidate, temferon, is currently in phase 1/2a for glioblastoma multiforme. It is idesigned to deliver IFN-α only at the tumor site. A data update is expected in this half of the year with enrollment completion in H1 2023. A phase 2 study is planned for H2 2023.
Analysis Article Mar 18

Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Financial Position Analysis

Short Term Liabilities: GNTA's short term assets (€30.0M) exceed its short term liabilities (€2.1M).

Long Term Liabilities: GNTA's short term assets (€30.0M) exceed its long term liabilities (€7.9M).


Debt to Equity History and Analysis

Debt Level: GNTA has more cash than its total debt.

Reducing Debt: GNTA's debt to equity ratio has increased from 0% to 34.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GNTA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GNTA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 6.1% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 22:28
End of Day Share Price 2026/06/03 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genenta Science S.p.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Charles ButlerRoth Capital Partners